Vysis ALK Break Apart FISH Probe Kit
Abbott Molecular, Inc. · Decision date Feb 18, 2026
What did the FDA decide?
FDA records P110012/S023 as a supplement to PMA P110012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 18, 2026.
FDA approval order statement
implementation of a secondary packaging process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Feb 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P110012/S023
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Molecular, Inc.
- Product code
- OWE
- Decision code
- OK30
- Decision date
- Feb 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement.
- Applicant
- Abbott Molecular, Inc.
- Product code
- OWE
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110012/S022 · Related supplement
Vysis ALK Break Apart FISH Probe Kit
P110012/S023 received
Application receipt date recorded by FDA.
P110012/S023 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P110012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Vysis ALK Break Apart FISH Probe KitP110012/S022 | Abbott Molecular, Inc. | PMA supplement | Aug 5, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P110012/S023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records